Literature DB >> 6743482

Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers.

C Staiger, B Korodnay, J X Devries, E Weber, P Müller, B Simon, H G Dammann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6743482      PMCID： PMC1463573          DOI： 10.1111/j.1365-2125.1984.tb05031.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  24 hour intragastric acidity and single night-time dose of three H-2-blockers.

Authors:  H G Dammann; P Müller; B Simon
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

2.  Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs.

Authors:  T Takagi; M Takeda; H Maeno
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-03
  2 in total
  11 in total

Review 1.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  Comparative effects of famotidine and cimetidine on 7-ethoxycoumarin O-deethylase activity in human livers.

Authors:  Y Imai; M Inada; S Tamura; S Kawata; Y Minami; S Tarui
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 3.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

4.  Famotidine does not affect indocyanine green disposition and serum bile acid levels in healthy subjects.

Authors:  R Testa; A Grasso; F Dagnino; R Ibba; G Varagona; G Celle
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

5.  A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow.

Authors:  N C Sambol; R A Upton; A N Chremos; E T Lin; R L Williams
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

6.  Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry.

Authors:  S R Brazer; M P Tyor; F S Pancotto; R S Brice; J T Garbutt; N M Wildermann; F E Harrell; D B Pryor; C L Liss; J K Root
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

7.  Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.

Authors:  U Klotz; P Arvela; B Rosenkranz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 9.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

10.  Effect of famotidine on oxidative drug metabolism.

Authors:  K W Somerville; G A Kitchingman; M J Langman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.